Cite
HARVARD Citation
Avogaro, A. et al. (2017). A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert review of clinical pharmacology. 10 (7), pp. 763-772. [Online].